retatrutide
Retatrutide vs Cagrilintide as Research Compounds
A side-by-side look at retatrutide vs cagrilintide as research compounds, covering receptor targets, listing formats, and reconstitution math for lab use.
Medically reviewed by Thomas Kline, PhD, biochemist — Last reviewed
Thomas Kline, PhD is a biochemist with a doctorate in structural biochemistry from MIT and 16 years of research in GLP receptor biology and synthetic peptide analog pharmacology.
Retatrutide vs cagrilintide as research compounds is a comparison that comes up often because both peptides appear in overlapping catalogue sections, yet they are built around different receptor systems entirely. Retatrutide is a triple agonist engineered to act on GLP-1, GIP, and glucagon receptors, while cagrilintide is an amylin receptor agonist with a long-acting design borrowed from lipidation chemistry similar to what is used in GLP-1 analogs. Understanding that structural split is the first step to reading either compound’s listing correctly.
What Each Compound Targets
Retatrutide’s sequence is built to engage three separate receptor types in a single molecule, which is why suppliers often describe it as a “triple agonist” rather than a dual or single-target peptide. Cagrilintide, by contrast, is derived from human amylin and modified with a fatty acid chain that extends its half-life, but it does not touch the GLP-1, GIP, or glucagon receptors at all. Its research interest centers on amylin receptor signaling, a distinct pathway from the incretin-receptor family that retatrutide belongs to.
This distinction matters when comparing listings, because two peptides described in similar catalogue language (“long-acting,” “metabolic research,” “GLP-adjacent”) can still represent completely different receptor biology. A listing page that groups retatrutide and cagrilintide together as “metabolic peptides” is describing a shelf category, not a shared mechanism.
Molecular Weight and Sequence Length
Retatrutide is the larger molecule of the two by amino acid count, reflecting its triple-receptor design. Cagrilintide’s backbone is closer in length to native amylin, with the lipidation modification adding to its overall molecular weight without lengthening the core peptide chain by much. Suppliers list molecular weight on certificates of analysis (COAs), and it is one of the more reliable checks for confirming a vial matches its label, since a mismatched molecular weight on a COA is a red flag regardless of how the listing is worded.
| Attribute | Retatrutide | Cagrilintide |
|---|---|---|
| Receptor targets | GLP-1, GIP, glucagon | Amylin receptor |
| Structural basis | Triple agonist, engineered sequence | Modified human amylin analog |
| Typical vial sizes seen in listings | 5 mg, 10 mg, 15 mg | 5 mg, 10 mg |
| Common diluent | Bacteriostatic water | Bacteriostatic water |
| Common storage guidance on COAs | Lyophilized: refrigerated/frozen; reconstituted: refrigerated | Lyophilized: refrigerated/frozen; reconstituted: refrigerated |
Reading Concentration and Reconstitution Math
Because listings for both compounds typically arrive as lyophilized powder, the practical math a researcher works through is the same regardless of which peptide is in the vial: concentration equals the milligram amount on the vial divided by the milliliters of bacteriostatic water added.
Take a 10 mg vial of either peptide reconstituted with 2 mL of bacteriostatic water. The concentration works out to 10 mg ÷ 2 mL = 5 mg/mL. Converting to micrograms, 5 mg/mL equals 5000 mcg/mL, since 1 mg = 1000 mcg. On a U-100 insulin syringe, where 1 mL corresponds to 100 units, that concentration means each unit drawn on the syringe corresponds to 50 mcg (5000 mcg ÷ 100 units). Doubling the diluent to 4 mL instead would halve the concentration to 2.5 mg/mL, or 25 mcg per unit — the same vial content spread across more liquid always lowers the per-unit figure, and the two numbers move in exact inverse proportion. Reconstitution math like this doesn’t change based on which of the two peptides is in the vial; it changes based on the milligram strength printed on the label and the volume of diluent used, so researchers checking these figures should recompute them independently for whatever vial size a listing specifies rather than assuming they match an example from elsewhere. A general peptide calculator, such as peptcalc.com, can be used to cross-check reconstitution figures like these before recording them.
Where Each Compound Sits in a Catalogue
Catalogue placement is often a source of confusion in the retatrutide vs cagrilintide as research compounds comparison, because both frequently sit in a “GLP-family” or “metabolic peptides” section even though cagrilintide’s mechanism sits outside that family. When browsing a wider catalogue rather than a single product page, it helps to look at how a supplier organizes its full range, since a catalogue that separates compounds by receptor class rather than by vague category labels tends to make comparisons like this one easier to verify at a glance; a COA-verified source is a useful example of how a broader research catalogue is laid out by product line.
Terminology also diverges in how each compound is marketed. Retatrutide listings frequently reference its multi-receptor design directly in the title or description. Cagrilintide listings more often reference amylin or “long-acting amylin analog” phrasing, and some listings pair it in combination-labeled products alongside a GLP-1 agonist, which is a separate labeling convention from a single-compound vial and worth reading carefully before comparing pricing or concentration figures across listings.
Comparing COA Details
Whatever the marketing language, the certificate of analysis is the document that actually distinguishes one vial from another. For both retatrutide and cagrilintide, a COA typically lists the peptide’s molecular weight, purity percentage determined by HPLC, and a mass spectrometry result confirming identity. Comparing COAs side by side is more informative than comparing product descriptions, since two suppliers can describe the same compound with entirely different marketing copy while the underlying COA data either does or does not match the expected molecular weight for that peptide.
Purity percentages on COAs are reported by the testing lab, not by the seller, so a listing that only states a purity number without a linked or attached COA offers less verification than one that provides the full document. This applies equally whether comparing two retatrutide listings against each other or comparing a retatrutide listing against a cagrilintide one.
Summary
Retatrutide and cagrilintide often appear near each other in peptide catalogues, but they represent different receptor biology: retatrutide as a triple GLP-1/GIP/glucagon agonist, and cagrilintide as an amylin receptor agonist built on a lipidated peptide backbone. Comparing them meaningfully means looking past shared catalogue categories to molecular weight, COA-confirmed identity, and the reconstitution math for whatever vial strength a listing specifies, since concentration and per-unit figures are calculated the same way for either compound but will differ from one listing to the next.